Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MEDI4736, MEDI4736 (Durvalumab)
MEDI4736 monotherapy · 1 trial · 1 indication
ORR was defined as the percentage of patients with at least one visit response of confirmed complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have had reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters. A confirmed response meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit and not less than 4 weeks after the visit when response was first observed with no evidence of progression between the initial and CR/PR confirmation visits. Results are reported as percentage of patients with a confirmed response and percentage of patients with confirmed or unconfirmed responses (i.e., including single visit responses).
| Arm | Type | Description |
|---|---|---|
| MEDI4736 monotherapy | EXPERIMENTAL | MEDI4736 via IV infusion. |
| tremelimumab+MEDI4736 | EXPERIMENTAL | MEDI4736+tremelimumab via IV infusion. |
| Name | Type | Description |
|---|---|---|
| MEDI4736 monotherapy | DRUG | MEDI4736 via IV infusion. |
| tremelimumab+MEDI4736 | DRUG | tremelimumab+MEDI4736 via IV infusion. |
Inclusion Criteria: - 1. Histologically or cytologically confirmed metastatic PDAC, no more than 1 prior chemotherapy regimen 2. Eastern Cooperative Oncology Group 0 or 1 3. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (...
MEDI4736, also known as durvalumab, is an investigational monoclonal antibody being studied for the treatment of several cancers, including non-small cell lung cancer, urothelial cancer, breast cancer, and recurrent or metastatic squamous cell carcinoma of the head and neck. It is currently in Phase 3 clinical development.
MEDI4736 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is an investigational monoclonal antibody in Phase 3 clinical trials for oncology indications.
MEDI4736 is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of various cancers, including non-small cell lung cancer and head and neck cancer.
MEDI4736 has been studied in several clinical trials, including NCT02352948, a Phase 3 study in non-small cell lung cancer with 597 participants, and NCT02369874, a Phase 3 study in head and neck cancer with 736 participants. Both trials have been completed.
Yes, MEDI4736 is also known as durvalumab. The drug is being developed by AstraZeneca PLC under the ticker AZN and is currently in Phase 3 clinical trials for multiple oncology indications, including non-small cell lung cancer and urothelial cancer.